Staphylococcus Epidermidis
US-FDASourced from openFDA
GET
/api/v1/drug/staphylococcus-epidermidisIndications
Sourced from openFDA- Rx Only*
Dosage & administration
Sourced from openFDAAdults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
486 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Diarrhoea336.8%
- 2Pain336.8%
- 3Headache306.2%
- 4Fatigue296.0%
- 5Nausea275.6%
- 6Arthralgia265.3%
- 7Dizziness255.1%
- 8Pain In Extremity214.3%
- 9Asthenia183.7%
- 10Abdominal Pain Upper173.5%
- 11Eye Pain173.5%
- 12Fall173.5%
- 13Gait Disturbance173.5%
- 14Muscle Spasms173.5%
- 15Dyspnoea163.3%
Literature
Recent PubMed references pinned to Staphylococcus Epidermidis as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- [Antibacterial activity and mechanism of the antiparasitic drug resorantel against Staphylococcus epidermidis].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026 · Guo S, Huang G, Xiao D, et al.PMID 42244287DOI 10.11817/j.issn.1672-7347.2026.250544
- Staphylococcus epidermidis prevents UV-induced skin aging by suppressing TLR3-mediated senescence.Frontiers in immunology · 2026 · Wang X, Wang M, Yang J, et al.PMID 42206047DOI 10.3389/fimmu.2026.1796085
- Anti-quorum-sensing activity of Plectranthus aliciae in multispecies Cutibacterium acnes-Staphylococcus epidermidis systems.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026 · Kupke IA, Spittaels KJ, Coenye T, et al.PMID 42119451DOI 10.1016/j.phymed.2026.158260
- Isolation and characterization of broad-range Staphylococcus epidermidis sepunaviruses.Microbiology (Reading, England) · 2026 · Valdivia C, Rimmer CO, Thomas JC, et al.PMID 42096338DOI 10.1099/mic.0.001693
- First report of bacteremia caused by CO(2)-dependent methicillin-resistant Staphylococcus epidermidis in a patient with symptomatic multiple myeloma.Diagnostic microbiology and infectious disease · 2026 · Iida T, Fujita T, Iwata A, et al.PMID 42061129DOI 10.1016/j.diagmicrobio.2026.117415
- Species diversity and antimicrobial susceptibility profiling of staphylococci isolated from camel milk in Algeria.Archives of Razi Institute · 2025 · Fetta M, Charhazed B, Nedjma L, et al.PMID 42058239DOI 10.32592/ARI.2025.80.4.1039
- Bacterial factors required for biofilm formation in Staphylococcus epidermidis are linked to contact activation.Frontiers in cellular and infection microbiology · 2026 · Rademacher A, Ekat K, Skusa R, et al.PMID 42058173DOI 10.3389/fcimb.2026.1802218
- Piezoelectric cold atmospheric plasma inactivates dairy cattle bacteria and potentiates antibiotics in vitro.Applied microbiology and biotechnology · 2026 · Ghodke JS, Teixeira DL, Enriquez-Hidalgo D, et al.PMID 42032177DOI 10.1007/s00253-026-13843-9
Clinical trials
The 10 most recently updated of 22 ClinicalTrials.gov registrations naming Staphylococcus Epidermidis as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective EndocarditisRecruiting · Phase 3 · Interventional · 30 enrolled · University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)NCT06870409updated 2026-03-19
- A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal ToxicityRecruiting · Phase 1 · Phase 2 · Interventional · 32 enrolled · Azitra Inc.NCT06830863updated 2026-02-11
- Evaluation of Topical ATR12-351 in Adults With Netherton SyndromeRecruiting · Phase 1 · Interventional · 12 enrolled · Azitra Inc.NCT06137157updated 2026-02-05
- Invasive Markers of Staphylococcus EpidermidisCompleted · Observational · 320 enrolled · Assistance Publique - Hôpitaux de ParisNCT03374371updated 2026-01-15
- Study to Evaluate the Safety of ATR-04Withdrawn · Phase 1 · Phase 2 · Interventional · 0 enrolled · Azitra Inc.NCT04731259updated 2025-10-03
- Staphylococcus Aureus in Atopic Dermatitis ImmunopathologyCompleted · Interventional · 7 enrolled · Hospices Civils de LyonNCT04715087updated 2025-09-11
- Cleanser for Acute WoundsWithdrawn · Interventional · 0 enrolled · Rochal Industries LLCNCT05422144updated 2025-05-04
- Use of Phage Therapy for Treatment of a Periprosthetic Joint InfectionActive not recruiting · Phase 1 · Interventional · 1 enrolled · Ottawa Hospital Research InstituteNCT06827041updated 2025-02-14
- Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood CellsUnknown · Phase 1 · Phase 2 · Interventional · 48 enrolled · Inmunotek S.L.NCT05208060updated 2024-09-19
- Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid PeriodCompleted · Observational · 342 enrolled · Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and ArthroplastyNCT06267287updated 2024-02-20
Frequently asked questions
- What is Staphylococcus Epidermidis used for?
- According to FDA labeling, Staphylococcus Epidermidis carries indications including: Rx Only*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
Note. Data for
staphylococcus-epidermidis is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.